Figure 4.

Ex vivo and in vivo efficacy of SI-12 (6c). (A) Images and quantification of prostate cancer PDX organoids treated by SI-12 (6c) and vehicle. SI-12 (6c) significantly inhibited the growth of organoids developed from prostate cancer PDX tumors. (B) Tumor volumes and (C) body weights were measured once per week in an orthotopic PDAC mouse model (n = 9). SI-12 (6c) can significantly inhibit tumor growth while not affecting mouse body weights. The treatment group was treated with SI-12 (10 mg/kg, i.p.) once per day (D) Representative images of harvested tumors and (E) Representative luciferase images after 8 weeks of treatment. Data represent mean ± SEM; *p < 0.05, **p < 0.005, ***p < 0.0005.